NasdaqCM:MLTXBiotechs
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 S-OLARIS Trial Results
MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after reporting positive topline results from its Phase 2 S-OLARIS trial in axial spondyloarthritis, where sonelokimab delivered clinically meaningful benefits and reduced key disease activity markers.
See our latest analysis for MoonLake Immunotherapeutics.
The latest S-OLARIS update comes after a strong run, with MoonLake’s 30 day share price return of 14.75% and 90 day share price return of 31.88%. However, its 1 year total...